Orchestra BioMed Holdings, Inc. (OBIO) AI Stock Analysis

Orchestra BioMed Holdings, Inc. is a therapeutic device company focused on advancing treatments for cardiovascular diseases. Based in New Hope, Pennsylvania, the firm develops bioelectronic therapies and drug/device combination products. Its pipeline includes the BackBeat Cardiac Neuromodulation Therapy (CNT) for hypertension management, the Virtue SAB for arterial disease, and the Virtue SEB drug-eluting balloon angioplasty system for coronary artery disease. The company collaborates with Medtronic to advance BackBeat CNT for hypertension patients eligible for cardiac pacemakers.

Revenue rose from -$782,000 in FY2021 to $3.5M in FY2022, before dropping to $2.8M in FY2023 and $2.6M in FY2024. In FY2025, revenue increased 1169.2% to $33.5M, reflecting a 5-year revenue CAGR of 42.5% from FY2020. However, the company remains unprofitable, posting an operating margin of -154.7% and net income of -$52.7M in FY2025 as R&D expense reached $58.2M. Over the trailing twelve months, revenue was $32.0M with an operating margin of -25404.5% and EPS of -$0.86. For the latest quarter ended June 30, 2026, quarterly revenue fell 89.5% year-over-year.

As of June 30, 2026, Orchestra BioMed held $110.0M in cash and short-term investments against total debt of $70.8M, resulting in net cash of $39.2M. The company reported total assets of $115.7M, shareholders' equity of $29.4M, a current ratio of 8.26, and a debt-to-equity ratio of 2.41. Free cash flow was -$49.5M in FY2025, with operating cash flow at -$49.0M and capital expenditures of $489,000. Over a 5-year period, the share count increased by 212.0%.

With a market cap of $327.6M and an enterprise value of $282.1M, Orchestra BioMed trades at a price-to-sales multiple of 10.2x and an EV-to-revenue multiple of 8.8x. These multiples sit above the median of its US-listed Healthcare peers, which have a price-to-sales multiple of 4.1x. Its price-to-book ratio is 18.4x. Over the past year, OBIO returned 48.1%, outperforming the S&P 500 (SPY) return of 16.8%, though its 5-year return of -44.7% trails the index return of 83.0%.

Wall Street coverage includes 6 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell recommendations. The mean price target is $12.43, representing a 128.0% premium over the last close of $5.45. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $451,140 and an EPS of -$1.52. For the next fiscal year, 6 analysts anticipate revenue of $600,140 and EPS of -$1.51. The company has beaten EPS estimates in 3 of the last 4 quarters, with the next earnings date scheduled for November 9, 2026.

This page is an AI-written research summary of Orchestra BioMed Holdings, Inc. (OBIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OBIO income statement, OBIO balance sheet, OBIO key metrics, OBIO analyst forecast, OBIO chart. See the OBIO stock overview for the latest quote and news.